MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

Now Viewing

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Strategies to mitigate talquetamab-induced taste changes include topical dexamethasone rinses, tart candies as taste stimulants, saliva substitutes, dietary changes, nutrition consult for at-risk patients, prompt oral thrush treatment, and icing salivary glands given observed uptake. However, no interventions are definitively effective. Alternate talquetamab scheduling helps some patients, particularly reducing frequency to every 2 weeks initially or monthly dosing once response is attained. Some taste improvement follows talquetamab discontinuation with recurrence upon restarting. Compared with talquetamab, chimeric antigen receptor T-cell therapy targeting GPRC5D shows less taste distortion, indicating schedule dependency of bispecific antibody–mediated changes. Overall, tailoring administration frequency appears most impactful to managing oral adverse events, as monthly talquetamab enabled improved tolerance.

Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.